Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data

Conditions

• Non-small Cell Lung Cancer

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Study Details

This research will leverage machine learning (ML) and causal inference techniques applied to real-world data (RWD) to generate evidence that personalizes treatment strategies for patients with advanced non-small cell lung cancer (aNSCLC). Rather than influencing regulatory decisions or clinical guidelines, the goal of this trial is to refine treatment selection among existing therapeutic options, ensuring that care is tailored to individual patient characteristics. Additionally, by generating real-world evidence, these findings will inform the design and implementation of future clinical trials. Importantly, the methodological advancements will establish a pipeline that extends beyond aNSCLC, facilitating the identification of optimal dynamic treatment regimes (DTRs) for other complex diseases.

Key Dates

Start date

Sep 1, 2024

Status verified

Apr 2026

Primary completion

Aug 31, 2027

Completion

Aug 31, 2027

Study Design

Enrollment

144,400 participants (estimated)

Arms

• Arm: Flatiron database
  The current study will utilize data from national EHR databases (Flatiron and CancerLinQ) and existing cohort data (HCI and MCC). Only de-identified data will be used, and no patients will be contacted during the study.
• Arm: CancerLinQ database
  The current study will utilize data from national EHR databases (Flatiron and CancerLinQ) and existing cohort data (HCI and MCC). Only de-identified data will be used, and no patients will be contacted during the study.
• Arm: Huntsman Cancer Institute (HCI) Cohort
  The current study will utilize data from national EHR databases (Flatiron and CancerLinQ) and existing cohort data (HCI and MCC). Only de-identified data will be used, and no patients will be contacted during the study.
• Arm: Moffitt Cancer Center (MCC) Cohort
  The current study will utilize data from national EHR databases (Flatiron and CancerLinQ) and existing cohort data (HCI and MCC). Only de-identified data will be used, and no patients will be contacted during the study.

Primary Outcome Measure

Overall Survival (OS) [ Time Frame: From the initiation of first-line therapy to death or the last follow-up, whichever occurs first, up to 10 years. ]

Locations (1)

Find similar trials in Salt Lake City, UT

Related Studies

• JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
  PHASE3 · Recruiting · University of Texas Southwestern Medical Center · La Jolla, California
• VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
  PHASE1/PHASE2 · Recruiting · VM Oncology, LLC · Santa Rosa, California
• Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
  PHASE1 · Recruiting · AbbVie · Duarte, California
• ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
  Recruiting · Guardant Health, Inc. · Birmingham, Alabama